Price Alert

Foghorn Therapeutics Inc. (FHTX)

NASDAQ: FHTX · Real-Time Price · USD

5.39

0.12 (2.28%)

At close: Sep 04, 2025, 3:59 PM

5.29

-1.86%

Pre-market: Sep 05, 2025, 08:54 AM EDT

2.28% (1D)

Bid	4.96
Market Cap	304.7M
Revenue (ttm)	24.17M
Net Income (ttm)	-75.39M
EPS (ttm)	-1.14
PE Ratio (ttm)	-4.73
Forward PE	-4.54
Analyst	Buy

Ask	5.6
Volume	36,508
Avg. Volume (20D)	116,495
Open	5.29
Previous Close	5.27
Day's Range	5.15 - 5.40
52-Week Range	2.94 - 10.25
Beta	3.05

About FHTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol FHTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for FHTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Foghorn Therapeutics Inc. is scheduled to release its earnings on Nov 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

8 months ago

+3.96%

Foghorn Therapeutics shares rare trading lower aft... Unlock content with Pro Subscription

News

3 days ago · zacks.com

Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

1 week ago · zacks.com

Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why

Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago · zacks.com

Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing

Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou...

1 month ago · zacks.com

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago.